Role of SMC1 in Overcoming Drug Resistance in Triple Negative Breast Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yadav, Sushma ^a   Sehrawat, Archana ^b   Eroglu, Zeynep ^a   Somlo, George ^a   Hickey, Robert ^a   Yadav, Sailee ^a   Liu, Xueli ^c   Awasthi, Yogesh C ^b   Awasthi, Sanjay ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c Beckman Research Institute of City of Hope ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; COHESIN; STRUCTURAL MAINTENANCE OF CHROMOSOME 1; UNCLASSIFIED DRUG; UVOMORULIN; VELIPARIB; VIMENTIN;

ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL FRACTIONATION; CELL LINE; CELL MIGRATION; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME REPRESSION; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRIPLE NEGATIVE BREAST CANCER;

BASE SEQUENCE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84878085569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064338     Document Type: Article

References (53)

1. Ossovskaya V, Wang Y, Budoff A, Xu Q, Lituev A, et al. (2011) Exploring molecular pathways of triple-negative breast cancer. Genes Cancer 2: 870-879.
2. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, et al. (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30: 1879-1887.
3. Thompson AM, Newman TJ, (2012) Milking the stroma in triple-negative breast cancer. Cell Cycle 11: 1487.
4. Stebbing J, Ellis P, (2012) An overview of drug development for metastatic breast cancer. Br J Nurs 21: S18-22.
5. Chu QD, King T, Hurd T, (2012) Triple-negative breast cancer. Int J Breast Cancer 12: 671-684.
6. Brouckaert O, Wildiers H, Floris G, Neven P, (2012) Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 4: 511-520.
7. Liu H, Scholz C, Zang C, Schefe JH, Habbel P, et al. (2012) Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res 32: 1627-1637.
8. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, et al. (2012) TBCRC 001: Randomized phase II study of cetuximab in combination With carboplatin in Stage IV triple-negative breast cancer. J Clin Oncol 30: 2615-2623.
9. O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, et al. (2010) A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28 (suppl) (): abstr 1005.
10. Somlo G, Sparano JA, Cigler T, Fleming GF, Luu TH, et al. (2012) ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial. J Clin Oncol 30 (suppl) (): abstr 1010.
11. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, et al. (2010) Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer,. J Clin Oncol 28: 1145-1153.
12. Tentori L, Graziani G, (2005) Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52: 25-33.
13. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244.
14. Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, et al. (2010) A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 28 (suppl) (): abstr 1019.
15. Yazdi PT, Wang Y, Zhao S, Patel N, Lee EY, et al. (2002) SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev 16: 71-82.
16. Michaelis C, Ciosk R, Nasmyth K, (1997) Cohesins: Chromosomal proteins that prevent premature separation of sister chromatids. Cell 91: 35-45.
17. Wetzer S, Lehane C, Uhlmann F, (2003) A model for ATP-hydrolysis dependent transport of DNA into cohesin ring. Curr Biol 13: 1930-1940.
18. Arumugam P, Gruber S, Tanaka K, Haering CH, Mechtler K, et al. (2003) ATP hydrolysis is required for cohesin's association with chromosomes. Curr Biol 13: 1941-1953.
19. Hirano T, (2006) At the heart of the chromosome: SMC proteins in action. Nat Rev Mol Cell Biol 7: 311-322.
20. Nasmyth K, Haering CH, (2005) The structure and function of smc and kleisin complexes. Annu Rev Biochem 74: 595-648.
21. Hopfner K-P, (2003) Chromosome cohesion: closing time dispatch. Curr Biol 13: R566-R568.
22. Liu Z, Scannell DR, Eisen MB, Tjian R, (2011) Control of embryonic stem cell lineage commitment by core promoter factor, TAF3. Cell 146: 720-731.
23. Rhodes JM, McEwan M, Horsfield JA, (2011) Gene regulation by cohesin in cancer: is the ring an unexpected party to proliferation? Mol Cancer Res 9: 1587-1607.
24. Rocquain J, Gelsi-Boyer V, Adélaïde J, Murati A, Carbuccia N, et al. (2010) Alteration of cohesin genes in myeloid diseases. Am J Hematol 85: 717-719.
25. Xu H, Tomaszewski JM, McKay MJ, (2011) Can corruption of chromosome cohesion create a conduit to cancer? Nat Rev Cancer 11: 199-210.
26. Hagemann C, Weigelin B, Schommer S, Schulze M, Al-Jomah N, et al. (2011) The cohesin-interacting protein, precocious dissociation of sisters 5A/sister chromatid cohesion protein 112, is up-regulated in human astrocytic tumors. Int J Mol Med 27: 39-51.
27. Unal E, Heidinger-Pauli JM, Kim W, Guacci V, Onn I, et al. (2008) A molecular determinant for the establishment of sister chromatid cohesion. Science 321: 566-569.
28. Yamamoto G, Irie T, Aida T, Nagoshi Y, Tsuchiya R, et al. (2006) Correlation of invasion and metastasis of cancer cells, and expression of the RAD21 gene in oral squamous cell carcinoma. Virchows Arch 448: 435-441.
29. Jeong H, Ryu YJ, An J, Lee Y, Kim A, (2012) Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathol 60: E87-95.
30. Atienza JM, Roth RB, Rosette C, Smylie KJ, Kammerer S, et al. (2005) Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol Cancer Ther 4: 361-368.
31. Xu H, Yan M, Patra J, Natrajan R, Yan Y, et al. (2011) Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Res 13: R9.
32. Ghiselli G, Iozzo RV, (2000) Overexpression of bamacan/SMC3 causes transformation. J Biol Chem 275: 20235-20238.
33. Ghiselli G, Coffee N, Munnery CE, Koratkar R, Siracusa LD, et al. (2003) The cohesin SMC3 is a target the for beta-catenin/TCF4 transactivation pathway. J Biol Chem 278: 20259-20267.
34. Yadav S, Singhal SS, Singhal J, Wickramarachchi D, Knutson E, et al. (2004) Identification of membrane-anchoring domains of RLIP76 using deletion mutant analyses. Biochemistry 43: 16243-16253.
35. Sambrook J, Fritsch EF, Miniatis T (1989) Molecular cloning: A laboratory manual, 2nd ed., cold spring harbor university, cold spring harbor, N.Y.
36. Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, et al. (2000) Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry 39: 9327-9334.
37. Singhal SS, Yadav S, Drake K, Singhal J, Awasthi S, (2008) Hsf-1 and POB1 induce drug-sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem 283: 9714-9729.
38. Singhal SS, Wickramarachchi D, Yadav S, Singhal J, Leake K, et al. (2011) Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis. Mol Cancer Ther 1: 16-28.
39. Minamide LS, Bamburg JR, (1990) A filter paper dye-binding assay for quantitative determination of protein without interference from reducing agents or detergents. Anal Biochem 190: 66-70.
40. Sehrawat A, Yadav S, Awasthi YC, Basu A, Warden C, et al. (2013) P300 Regulates the Human RLIP76 Promoter Activity and Gene Expression. Biochem Pharmacol 85: 1203-1211.
41. Yadav S, Singhal J, Singhal SS, Awasthi S, (2009) hSET1: A novel approach for colon cancer therapy. Biochem Pharmacol 77: 1635-1641.
42. Singhal SS, Yadav S, Singhal J, Sahu M, Awasthi YC, et al. (2009) RLIP76: A target for kidney cancer therapy. Cancer Res 69: 4244-4251.
43. Walsh SB, Xu J, Xu H, Kurundkar AR, Maheshwari A, et al. (2011) Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFβ signaling pathway. Mol Carcinog 50: 516-527.
44. Boreddy SR, Sahu RP, Srivastava SK, (2011) Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS One 6: e25799.
45. Coene ED, Gadelha C, White N, Malhas A, Thomas B, et al. (2011) A novel role for BRCA1 in regulating breast cancer cell spreading and motility. JCB 192: 497-512.
46. Couchman JR, Kapoor R, Sthanam M, Wu RR, (1996) Perlecan and basement membrane-chondroitin sulfate proteoglycan (bamacan) are two basement membrane chondroitin/dermatan sulfate proteoglycans in the Engelbreth-Holm-Swarm tumor matrix. J Biol Chem 271: 9595-9602.
47. Wu RR, Couchman JR, (1997) cDNA cloning of the basement membrane chondroitin sulfate proteoglycan core protein, bamacan: a five domain structure including coiled-coil motifs. J Cell Biol 136: 433-444.
48. Bard M, Hegmans J, Hemmes A, Luider T, Willemsen R, et al. (2004) Proteomic Analysis of Exosomes Isolated from Human Malignant Pleural Effusions. Am J Respir Cell Mol Biol 31: 114-121.
49. Telli ML, Ford JM, (2010) PARP inhibitors in breast cancer. Clin Adv Hematol Oncol 8: 629-635.
50. NCT01445418. A phase I study with an expansion cohort of the PARP inhibitor AZD2281 combined with carboplatin in BRCA1/2 familial breast and ovarian cancer and sporadic tTriple negative breast and ovarian cancer from clinicaltrials.gov, accessed 10/2012:http://clinicaltrials.gov/ct2/show/NCT01445418.
51. NCT01149083. Randomized phase II trial of ABT-888 vs. ABT-888 in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. From clinicaltrials.gov, accessed 10/2012: http://clinicaltrials.gov/ct2/show/NCT01149083.
52. McLellan J, O'Neil N, Barrett I, Ferree E, van Pel DM, et al. (2012) Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 8: e1002574.
53. Lehmann BD, Bauer JA, Chen Xi, Sanders ME, Chakravarthy AB, et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.